Organon & Co (OGN)
18.07
-0.71
(-3.78%)
USD |
NYSE |
Nov 01, 16:00
18.02
-0.05
(-0.28%)
After-Hours: 20:00
Organon Gross Profit Margin (Quarterly): 58.34% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 58.34% |
| June 30, 2024 | 58.43% |
| March 31, 2024 | 59.00% |
| December 31, 2023 | 57.26% |
| September 30, 2023 | 59.71% |
| June 30, 2023 | 60.20% |
| March 31, 2023 | 62.29% |
| December 31, 2022 | 60.00% |
| September 30, 2022 | 64.15% |
| June 30, 2022 | 62.90% |
| Date | Value |
|---|---|
| March 31, 2022 | 64.20% |
| December 31, 2021 | 62.63% |
| September 30, 2021 | 61.94% |
| June 30, 2021 | 63.45% |
| March 31, 2021 | 60.76% |
| December 31, 2020 | 63.67% |
| September 30, 2020 | 66.83% |
| June 30, 2020 | 69.86% |
| March 31, 2020 | 69.78% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
57.26%
Minimum
Dec 2023
69.86%
Maximum
Jun 2020
62.39%
Average
62.29%
Median
Mar 2023
Gross Profit Margin (Quarterly) Benchmarks
| Eli Lilly and Co | 81.02% |
| Biomarin Pharmaceutical Inc | 74.73% |
| Cassava Sciences Inc | -- |
| Ligand Pharmaceuticals Inc | 93.00% |
| TG Therapeutics Inc | 88.70% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 25.02K% |
| Return on Assets | 10.87% |
| Return on Invested Capital | 14.93% |
| Profit Margin (Quarterly) | 22.69% |
| Operating Margin (Quarterly) | 24.65% |
| Return on Net Operating Assets | 13.91% |